(1S,9aR,11aS)-6-Chloro-9a,11a-dimethyl-7-oxo-2,3,3a,3b,4,5,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-cyclopenta[i]phenanthridine-1-carboxylic acid (2,5-bis-trifluoromethyl-phenyl)-amide

ID: ALA282037

Max Phase: Preclinical

Molecular Formula: C27H29ClF6N2O2

Molecular Weight: 562.98

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  C[C@]12CCC(=O)C(Cl)=C1NCC1C2CC[C@@]2(C)C1CC[C@@H]2C(=O)Nc1cc(C(F)(F)F)ccc1C(F)(F)F

Standard InChI:  InChI=1S/C27H29ClF6N2O2/c1-24-9-7-16-14(12-35-22-21(28)20(37)8-10-25(16,22)2)15(24)5-6-18(24)23(38)36-19-11-13(26(29,30)31)3-4-17(19)27(32,33)34/h3-4,11,14-16,18,35H,5-10,12H2,1-2H3,(H,36,38)/t14?,15?,16?,18-,24+,25-/m1/s1

Standard InChI Key:  WBCLDSQCYODIIE-FYXKBQMPSA-N

Molfile:  

     RDKit          2D

 38 42  0  0  1  0  0  0  0  0999 V2000
    3.8542   -6.3625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.8542   -5.5375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0042   -4.3167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1417   -6.7667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7625   -1.4667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5667   -6.7750    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.5667   -5.1250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0000   -5.1417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0042   -2.2542    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0000   -3.2667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9542   -1.2792    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2792   -5.5417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7917   -4.0667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1750   -2.0250    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7917   -3.0500    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.2792   -6.3667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4375   -6.3625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3667   -1.8375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.3000   -3.8917    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1417   -5.1167    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8042   -2.4417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5750   -4.3000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.7792   -5.4042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3250   -0.8625    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.2667   -4.7417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4167   -2.6875    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.4375   -5.5375    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1292   -1.0500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1500   -7.5917    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
    1.7167   -6.7750    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.4000   -1.8917    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    7.3417   -0.5542    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    6.7167   -0.4917    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    9.7875   -2.7542    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   10.4167   -2.8125    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   10.7375   -1.4167    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    3.8500   -4.7125    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.0000   -3.4917    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  0
  3  8  1  0
  4  1  2  0
  5  9  1  0
  6  1  1  0
  7  2  1  0
  8 12  1  0
  9 15  1  0
 13 10  1  1
 11  5  1  0
 12 16  1  0
 13  3  1  0
 14 18  1  0
 15 10  1  0
 16  6  1  0
 17  4  1  0
 18 21  1  0
 19 22  1  0
 20  2  1  0
 21  9  2  0
 22  7  1  0
 23  8  1  0
 24  5  2  0
 25 23  1  0
 26 10  2  0
 27 17  1  0
 28 18  2  0
 29  4  1  0
 30 17  2  0
 31 11  1  0
 32 11  1  0
 33 11  1  0
 34 14  1  0
 35 14  1  0
 36 14  1  0
  2 37  1  1
  3 38  1  1
 12  7  1  0
 27 20  1  0
 19  3  1  0
 13 25  1  0
 28 24  1  0
M  END

Alternative Forms

  1. Parent:

    ALA282037

    ---

Associated Targets(Human)

SRD5A1 Tclin Steroid 5-alpha-reductase 1 (755 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SRD5A2 Tclin Steroid 5-alpha-reductase 2 (937 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HSD3B1 Tchem 3-beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type I (15 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Biocomponents

Calculated Properties

Molecular Weight: 562.98Molecular Weight (Monoisotopic): 562.1822AlogP: 7.14#Rotatable Bonds: 2
Polar Surface Area: 58.20Molecular Species: NEUTRALHBA: 3HBD: 2
#RO5 Violations: 2HBA (Lipinski): 4HBD (Lipinski): 2#RO5 Violations (Lipinski): 2
CX Acidic pKa: 12.57CX Basic pKa: CX LogP: 5.90CX LogD: 5.90
Aromatic Rings: 1Heavy Atoms: 38QED Weighted: 0.38Np Likeness Score: 0.29

References

1. Kenny B, Ballard S, Blagg J, Fox D..  (1997)  Pharmacological options in the treatment of benign prostatic hyperplasia.,  40  (9): [PMID:9135028] [10.1021/jm960697s]
2. Guarna, A A and 8 more authors.  2000-10-05  Benzo[c]quinolizin-3-ones: a novel class of potent and selective nonsteroidal inhibitors of human steroid 5alpha-reductase 1.  [PMID:11020287]
3. Hartmann, R W RW and 5 more authors.  2000-11-02  Synthesis and evaluation of novel steroidal oxime inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase) and 5 alpha-reductase types 1 and 2.  [PMID:11063622]
4. Occhiato, Ernesto G EG and 11 more authors.  2004-07-01  Synthesis, biological activity, and three-dimensional quantitative structure-activity relationship model for a series of benzo[c]quinolizin-3-ones, nonsteroidal inhibitors of human steroid 5alpha-reductase 1.  [PMID:15214782]
5. Handratta, Venkatesh D VD and 10 more authors.  2005-04-21  Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.  [PMID:15828836]
6. Lao, Kejing K and 6 more authors.  2017-09-01  Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.  [PMID:28757062]

Source